Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology News Central (ONC)Darolutamide Prolongs Survival Regardless of mHSPC Risk or Volume

The ideal regimen recommended by the guidelines for those with metastatic hormone-sensitive prostate cancer (mHSPC) is darolutamide, ADT, and docetaxel. The combination of ADT and androgen receptor pathway inhibition, which was the norm at the start of the ARASENS trial, has changed the therapeutic landscape for mHSPC; this analysis offers crucial information for choosing the right course of action for particular patients.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form